Jitendra Sriram, MD & Head of Research of HSBC India told CNBC-TV18, "Sun Pharmaceutical is one name that is part of our Asia Super 10 as well and we continue to like. Probably one aspect is that the traction that is coming through from its acquired subsidiary in US, Taro continues to be very strong."
"We do like some midcap exposures there as well names like Lupin etc which are some names that we back," he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
